# Angiodynamics Inc. (ANGO)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $493M  
**Price:** $12.08 (-1.63%)

> AngioDynamics Inc. is a medical technology company that designs, manufactures, and sells medical, surgical, and diagnostic devices for treating peripheral vascular disease, oncology, and surgical applications in the United States and internationally. The company focuses on restoring healthy blood flow in the body's vascular system, expanding cancer treatment options, and improving patient quality of life through innovative minimally invasive solutions. Key products include the Auryon Atherectomy system, which uses optimized wavelength and short pulse width to remove lesions while preserving vessel wall endothelium, and the AlphaVac mechanical thrombectomy system for emergent aspiration in thrombus management. Its portfolio also encompasses ablation systems, fluid management systems, vascular access products, angiographic devices, drainage solutions, thrombolytics, and venous products. Operating through Med Tech and Med Device segments, AngioDynamics Inc. supports healthcare professionals worldwide with facilities in North America, Europe, APAC, the Middle East, and South America. Founded in 1988 and headquartered in Latham, New York, it remains a key player in the medical devices sector serving peripheral vascular and oncology needs.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $292M | $158M | -$40M | -$34M | — |
| 2024 | $304M | $155M | -$192M | -$184M | — |
| 2023 | $339M | $174M | -$51M | -$52M | — |
| 2022 | $316M | $166M | -$28M | -$27M | — |
| 2021 | $291M | $157M | -$35M | -$32M | — |
| 2020 | $264M | $150M | -$167M | -$167M | — |
| 2019 | $271M | $156M | -$9M | $61M | — |
| 2018 | $262M | $144M | -$14M | $16M | — |
| 2017 | $270M | $144M | -$11M | $5M | — |
| 2016 | $354M | $174M | $1M | -$44M | — |
| 2015 | $357M | $176M | -$3M | -$3M | — |
| 2014 | $354M | $180M | $10M | $2M | — |
| 2013 | $342M | $169M | $5M | -$1M | — |
| 2012 | $222M | $125M | -$5M | -$5M | — |
| 2011 | $216M | $126M | $12M | $8M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $280M | $97M | $183M | $56M | — |
| 2024 | $318M | $112M | $206M | $76M | — |
| 2023 | $533M | $154M | $378M | $45M | $50M |
| 2022 | $553M | $128M | $424M | $29M | $25M |
| 2021 | $561M | $122M | $439M | $48M | — |
| 2020 | $594M | $139M | $455M | $54M | — |
| 2019 | $836M | $222M | $615M | $228M | $132M |
| 2018 | $705M | $163M | $543M | $74M | $92M |
| 2017 | $708M | $193M | $515M | $48M | $96M |
| 2016 | $726M | $219M | $507M | $32M | — |
| 2015 | $773M | $228M | $545M | $18M | — |
| 2014 | $799M | $262M | $537M | $18M | $143M |
| 2013 | $791M | $264M | $526M | $16M | $143M |
| 2012 | $720M | $197M | $523M | $24M | $150M |
| 2011 | $437M | $32M | $406M | $46M | $6M |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$10M | $4M | -$15M |
| 2024 | -$28M | $3M | -$31M |
| 2023 | $78,000 | $4M | -$4M |
| 2022 | -$7M | $4M | -$11M |
| 2021 | $24M | $5M | $19M |
| 2020 | -$15M | $7M | -$22M |
| 2019 | $37M | $3M | $34M |
| 2018 | $41M | $2M | $39M |
| 2017 | $56M | $3M | $53M |
| 2016 | $45M | $2M | $43M |
| 2015 | $26M | $11M | $14M |
| 2014 | $25M | $11M | $14M |
| 2013 | $27M | $12M | $15M |
| 2012 | $12M | $2M | $9M |
| 2011 | $34M | $3M | $31M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ANGO)